| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Beata Matuszek, Monika Lenart-Lipińska, Andrzej Nowakowsk. [Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins - new possibilities for pharmacotherapy of type 2 diabetes]. Endokrynologia Polska. vol 59. issue 4. 2009-02-05. PMID:18777503. |
it is hypothesized that at the basis of this pathology lies an incretin defect of insulinotropic gut-derived hormones, relying on decreased secretion of glp-1 (glucagon-like peptide 1), with preserved insulinotropic effect, whereas gip (glucose-dependent insulinotropic polypeptide) secretion remains within physiological limits, but its action is mostly impaired due to total loss of possibility for stimulation of the second phase insulin secretion. |
2009-02-05 |
2023-08-12 |
human |
| Jerry R Greenfield, I Sadaf Farooqi, Julia M Keogh, Elana Henning, Abdella M Habib, Anthea Blackwood, Frank Reimann, Jens J Holst, Fiona M Gribbl. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. The American journal of clinical nutrition. vol 89. issue 1. 2009-02-05. PMID:19056578. |
incretin hormones, such as glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), play an important role in meal-related insulin secretion. |
2009-02-05 |
2023-08-12 |
human |
| Andrew J Krentz, Mayank B Patel, Clifford J Baile. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. vol 68. issue 15. 2009-01-30. PMID:18840004. |
glp-1 receptor agonists, such as exenatide, stimulate nutrient-induced insulin secretion and reduce inappropriate glucagon secretion while delaying gastric emptying and reducing appetite. |
2009-01-30 |
2023-08-12 |
Not clear |
| E Mannucci, C M Rotell. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutrition, metabolism, and cardiovascular diseases : NMCD. vol 18. issue 9. 2009-01-27. PMID:18849155. |
glucagon-like peptide-1 (glp-1), a gastrointestinal hormone mainly produced in the post-prandial state, reduces blood glucose through the stimulation of insulin secretion and the inhibition of glucagon release. |
2009-01-27 |
2023-08-12 |
Not clear |
| Ralph A DeFronzo, Ted Okerson, Prabhakar Viswanathan, Xuesong Guan, John H Holcombe, Leigh MacConel. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Current medical research and opinion. vol 24. issue 10. 2009-01-23. PMID:18786299. |
this study evaluated the effects of exenatide, a glp-1 receptor agonist, and sitagliptin, a dpp-4 inhibitor, on 2-h postprandial glucose (ppg), insulin and glucagon secretion, gastric emptying, and caloric intake in t2d patients. |
2009-01-23 |
2023-08-12 |
Not clear |
| Raja Padidela, Michael Patterson, Nawfal Sharief, Mohammed Ghatei, Khalid Hussai. Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period. European journal of endocrinology. vol 160. issue 1. 2009-01-15. PMID:18952761. |
glucagon-like peptide 1 (glp-1) is an incretin hormone that stimulates glucose-induced insulin secretion, increases beta-cell proliferation, neogenesis and beta-cell mass. |
2009-01-15 |
2023-08-12 |
Not clear |
| Frank Reimann, Abdella M Habib, Gwen Tolhurst, Helen E Parker, Gareth J Rogers, Fiona M Gribbl. Glucose sensing in L cells: a primary cell study. Cell metabolism. vol 8. issue 6. 2009-01-15. PMID:19041768. |
glucagon-like peptide-1 (glp-1) is an enteric hormone that stimulates insulin secretion and improves glycaemia in type 2 diabetes. |
2009-01-15 |
2023-08-12 |
mouse |
| Li Li, Ren Lili, Qi Hui, Wang Min, Wen Xue, Shen Xin, Liu Jing, Li Yan, Liu Yeqiang, He Fenrong, Li Furong, Shen Guanxi. Combination of GLP-1 and sodium butyrate promote differentiation of pancreatic progenitor cells into insulin-producing cells. Tissue & cell. vol 40. issue 6. 2009-01-09. PMID:18573514. |
we demonstrated that the combination of glp-1 and sodium butyrate resulted in the increasing of levels of transcripts encoding pancreatic developmental factors and insulin. |
2009-01-09 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
low, but physiological, concentration of glp-1 stimulates insulin secretion independent of the camp-dependent protein kinase pathway. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
glucagon-like peptide-1 (glp-1) induces pancreatic insulin secretion via the camp-dependent protein kinase (pka) pathway. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
in this study, we examined the glp-1 action mechanism at a physiological concentration on insulin secretion. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
a high concentration of glp-1 (10 nm) stimulated intracellular camp accumulation and insulin secretion was significantly inhibited by kt5720, a selective inhibitor of pka. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
low glp-1 concentrations (1 pm) also increased insulin secretion without significant accumulation of intracellular camp, and kt5720 did not affect insulin secretion. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
insulin secretion stimulated by 1 pm glp-1 was reduced by inhibitors of calcium action, including verapamil, dantrolene, and bapta. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
thus, we concluded that relatively low glp-1 concentrations-comparable to in vivo blood concentrations-promoted insulin secretion independent of the camp-pka pathway. |
2009-01-07 |
2023-08-12 |
Not clear |
| Makoto Shigeto, Masashi Katsura, Masafumi Matsuda, Seitaro Ohkuma, Kohei Kak. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. Journal of pharmacological sciences. vol 108. issue 3. 2009-01-07. PMID:18987435. |
the results of the present study may further the understanding of the dose-dependent response of glp-1 signal transducing pathways and the complicated mechanism of insulin secretion. |
2009-01-07 |
2023-08-12 |
Not clear |
| Adriano Maida, Julie A Lovshin, Laurie L Baggio, Daniel J Drucke. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology. vol 149. issue 11. 2009-01-06. PMID:18669601. |
glucagon-like peptide-1 (glp-1), a 30-amino-acid peptide regulates glucose homeostasis via control of insulin and glucagon secretion and by inhibition of gastric emptying and food intake. |
2009-01-06 |
2023-08-12 |
mouse |
| Raúl A Bastarrachea, Julio C Montero, Ictor Saavedra-Gajardo, Ricardo Cerda-Flores, Anselmo Machado-Domínguez, Anthony G Comuzzi. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity]. Revista medica de Chile. vol 136. issue 1. 2008-11-24. PMID:18483661. |
defective glucose-stimulated insulin secretion by pancreatic b-cells could be alleviated with recombinant glucagon-like peptide (glp-1) or agonists to the glp-1 receptor. |
2008-11-24 |
2023-08-12 |
Not clear |
| Richard D Carr, Marianne O Larsen, Maria Sörhede Winzell, Katarina Jelic, Ola Lindgren, Carolyn F Deacon, Bo Ahré. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. American journal of physiology. Endocrinology and metabolism. vol 295. issue 4. 2008-11-17. PMID:18612044. |
following water ingestion, glucose, insulin, glucagon, glp-1, and gip levels and dpp-4 activity were stable during the 5-h study period. |
2008-11-17 |
2023-08-12 |
Not clear |
| Richard D Carr, Marianne O Larsen, Maria Sörhede Winzell, Katarina Jelic, Ola Lindgren, Carolyn F Deacon, Bo Ahré. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. American journal of physiology. Endocrinology and metabolism. vol 295. issue 4. 2008-11-17. PMID:18612044. |
both fat and protein ingestion increased insulin, glucagon, gip, and glp-1 levels without affecting glucose levels or dpp-4 activity. |
2008-11-17 |
2023-08-12 |
Not clear |